Pharsight

Meridian Medcl patents expiration

1. Alsuma patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7811254 MERIDIAN MEDCL Autoinjector with needle depth adapter
Aug, 2027

(3 years from now)

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Market Authorisation Date: 29 June, 2010

Treatment: Acute treatment of migraine attacks, with or without aura, and the treatment of cluster headache episodes

Dosage: INJECTABLE;SUBCUTANEOUS

More Information on Dosage

ALSUMA family patents

Family Patents